New York, June 4, 2026, 08:05 (EDT)
- Splash Beverage finished 71.0% higher on Wednesday and was indicated up again in premarket action ahead of the NYSE American open.
- The company said it has sent in a plan to get back in line with the NYSE American’s stockholders’ equity rules.
- Medterra CBD’s earlier letter of intent is now expired, so its cannabinoid-wellness plans rely on fresh negotiations and financing.
Splash Beverage Group (SBEV) shares jumped again in premarket trade Thursday after the company said it filed a compliance plan with NYSE American and is still working on deals in cannabinoid wellness. SBEV gained 71.0% Wednesday to finish at $0.2420. The stock was quoted at $0.3650 premarket as of 7:42 a.m. EDT.
The timing is key, with the rally more about staying listed, making a deal, and getting enough capital to keep going than about selling drinks. The NYSE regular session was still closed at the dateline; core hours on the exchange are 9:30 a.m. to 4:00 p.m. Eastern.
Splash said NYSE Regulation notified the company on April 29 that it was out of compliance with continued listing standards linked to stockholders’ equity, or assets minus liabilities. Splash sent in its compliance plan May 28. If the NYSE accepts it, the company could have until Jan. 29, 2027, to resolve the issue.
The Fort Lauderdale, Florida-based company said its non-binding letter of intent with Medterra CBD expired May 4 without a final deal. The company said the letter was non-exclusive and it remains in talks with several other potential partners in the cannabinoid wellness sector.
Splash interim CEO Brady Cobb said the company is moving ahead “on multiple fronts” and described the NYSE plan as an “important milestone.” Cobb said Splash is looking for any deal to be “strategically compelling” and “financially responsible.”
Investors are zoning in on Splash’s balance sheet after the latest quarterly numbers came in. The company posted first-quarter net revenue of $4,224—well below last year’s $68,606—and reported a net loss from continuing operations of $2.14 million.
Splash said in the filing it is distributing only one product right now, Chispo tequila. First-quarter revenue came from sales to Senor Frog locations. The company said slow beverage sales have pushed it to look at regulated wellness and cannabinoid markets.
Cash was tight. Splash reported $381,195 in cash and cash equivalents at March 31, saying it didn’t have enough capital to cover working-capital needs for the 12 months after filing. Before the Medterra letter expired, the company also said it required about $10 million to finish that deal.
Splash is looking to shift its business into an already packed part of the public markets. Tilray Brands says it’s a global consumer-products player with a wellness angle, Canopy Growth calls itself a cannabis company with a focus on wellness and cannabis goods. Splash wants to move in that direction, but it’s coming from a smaller, more financially pressured position.
But none of this is guaranteed. NYSE American could turn down the compliance plan. There’s a chance deal talks break down with no agreement, and new capital would mean dilution for current shareholders. The company itself points to risks with fundraising, staying listed, finishing transactions, and dealing with changing cannabinoid rules.
The next question for markets is if the premarket interest sticks when the market opens. The bigger issue for Splash is if it can turn a compliance plan and talks into enough equity, cash, and operating muscle to save its listing.
